Publication: Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms
Open/View Files
Date
2014
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Schneider, R. K., S. Ziegler, I. Leisten, M. S. Ferreira, A. Schumacher, B. Rath, D. Fahrenkamp, et al. 2014. “Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms.” Journal of Hematology & Oncology 7 (1): 92. doi:10.1186/s13045-014-0092-2. http://dx.doi.org/10.1186/s13045-014-0092-2.
Research Data
Abstract
We characterized bone marrow stromal cells (BMSC) from patients with pre-fibrotic myeloproliferative neoplasms (MPN). MPN-BMSC showed decreased capacity to stimulate the proliferation of colony-forming units of normal hematopoietic stem and progenitor cells and displayed increased matrix remodelling (in particular fibronectin deposition) compared to control BMSC. This finding was confirmed in pre-fibrotic MPN bone marrow biopsies in a tissue microarray (n = 34), which stained positive for fibronectin in the absence of reticulin as a standard myelofibrosis marker. Fibronectin expression correlated significantly with reduced haemoglobin levels in MPN-patients (p = 0.007; R2 = 0.42). Our data show significant cell-intrinsic alterations in MPN-MSC and suggest that Fibronectin expression might be applicable as a biomarker for the identification of early myelofibrotic transformation in reticulin-negative MPN.
Description
Other Available Sources
Keywords
Myeloproliferative neoplasms, Myelofibrosis, Mesenchymal stromal cells, Tissue microarray biomarker, Fibronectin
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service